Sort   by:  
 Page size 
ProteomicsIn-depth proteomic analyses reveal unique subtype-specific signatures in small cell lung cancer (part II: cell media)
Small-cell lung cancer (SCLC) represents about 13–15% of all lung cancers and with a five-year survival rate of less than 7%, it remains one of the most lethal forms of malignant diseases. It has a very aggressive course and is characterized by extensive chromosomal rearrangements, high mutation bur...
ORGANISM(S): Homo sapiens (Human) 
2022-10-14 | PXD029821 | Pride
Sclc Proteomics Cell lines Molecular subtypes 
ProteomicsIn-depth proteomic analyses reveal unique subtype-specific signatures in small cell lung cancer (part I: cell pellets)
Small-cell lung cancer (SCLC) represents about 13–15% of all lung cancers and with a five-year survival rate of less than 7%, it remains one of the most lethal forms of malignant diseases. It has a very aggressive course and is characterized by extensive chromosomal rearrangements, high mutation bur...
ORGANISM(S): Homo sapiens (Human) 
2022-10-14 | PXD029805 | Pride
Sclc Proteomics Cell lines Molecular subtypes 
ProteomicsProteomic characterization of primary and brain metastatic lung adenocarcinomas in a well-defined patient cohort
Lung adenocarcinoma (LADC) is the most common subtype of non-small cell lung cancer (NSCLC). One major feature of disease progression is the metastatic spread to the central nervous system (CNS). Treatment regimens for brain metastases are limited, thus distant metastases remain the leading cause of...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD027259 | Pride
Cancer progression Ffpe samples Lung adenocarcinoma Clinical proteomics Brain metastasis 
Sort   by:  
 Page size